|Articles|March 15, 2004

FDA extends review of Vitrase by 90 days

Irvine, CA-The FDA is extending its review of ISTA Pharmaceuticals Inc.'s new drug application for Vitrase for use as a spreading agent by 90 days to allow for a full review.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME